首页 | 本学科首页   官方微博 | 高级检索  
     

16例乳腺化生性癌的临床病理分析及EMT相关指标的表达
引用本文:罗 波1,陈佳梅2,朱广伟3,李 莉1,曾 盼1,文登虎1,刘 杰1,章宏峰1. 16例乳腺化生性癌的临床病理分析及EMT相关指标的表达[J]. 现代肿瘤医学, 2018, 0(3): 370-374. DOI: 10.3969/j.issn.1672-4992.2018.03.012
作者姓名:罗 波1  陈佳梅2  朱广伟3  李 莉1  曾 盼1  文登虎1  刘 杰1  章宏峰1
作者单位:1.华中科技大学同济医学院附属武汉市中心医院病理科,湖北 武汉 4300142.武汉大学人民医院肿瘤科,湖北 武汉 4300603.福建医科大学附属第一医院胃肠外科,福建 福州 350005
基金项目:福建省自然科学基金(编号:2017J01279)
摘    要:目的:研究乳腺化生性癌(metaplastic carcinoma of the breast,MBC)的临床病理特征,并探讨上皮间质转化(epithelial-mesenchymal transformation,EMT)指标E-钙黏蛋白(E-cadherin)与波形蛋白(Vimentin)在MBC和乳腺浸润性导管癌(invasive ductal carcinoma of the breast,IDC)中的差异性表达。方法:回顾性分析16例MBC患者的临床病理资料;同时选取与上述MBC临床病理特征匹配的16例IDC作为对照组。采用免疫组化SP法检测上述两组病例癌组织中ER、PR、HER-2、Ki-67、E-cadherin以及Vimentin的表达情况。结果:16例MBC中4例为纯鳞状细胞癌,4例为鳞状细胞癌伴有非特殊性浸润性癌,7例为梭形细胞癌,1例为混合型;患者中位发病年龄51岁,中位最大直径3.8 cm,淋巴结阳性率43.8%;ER/PR阳性率为0,HER-2阳性率为18.8%,13例为三阴性乳腺癌。E-cadherin在MBC组中的正常表达率低于IDC组(0% vs 37.5%,P<0.05);Vimentin在MBC组中表达增加,强于IDC组(P<0.05)。结论:MBC是一种罕见的特殊类型的浸润性乳腺癌,形态学异质性明显,激素受体低表达,分子分型以三阴性癌为主;另外MBC中EMT程度明显高于IDC,故其预后较IDC差。

关 键 词:乳腺癌  化生性癌  免疫组化  上皮间质转化

An analysis of 16 metaplastic breast carcinomas clinicopathologic features and expression of EMT markers
Luo Bo1,Chen Jiamei2,Zhu Guangwei3,Li Li1,Zeng Pan1,Wen Denghu1,Liu Jie1,Zhang Hongfeng1. An analysis of 16 metaplastic breast carcinomas clinicopathologic features and expression of EMT markers[J]. Journal of Modern Oncology, 2018, 0(3): 370-374. DOI: 10.3969/j.issn.1672-4992.2018.03.012
Authors:Luo Bo1  Chen Jiamei2  Zhu Guangwei3  Li Li1  Zeng Pan1  Wen Denghu1  Liu Jie1  Zhang Hongfeng1
Affiliation:1.Department of Pathology,The Central Hospital of Wuhan,Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430014,China;2.Center of Oncology,Renmin Hospital of Wuhan University,Hubei Wuhan 430060,China;3.Department of Gastroi
Abstract:Objective:To review the clinicopathologic features of patients with metaplastic carcinoma of the breast (MBC) at our institution,and evaluate the differential expression of epithelial-mesenchymal transformation (EMT) makers namely E-cadherin and Vimentin in MBC and invasive ductal carcinoma of the breast (IDC).Methods:Clinical pathologic data of MBC and clinicopathologic-matched IDC were searched from 2008 to 2015.Expression of ER,PR,HER-2,Ki-67,E-cadherin and Vimentin were evaluated by immunohistochemistry.Results:Sixteen MBC were searched,including 4 pure squamous,4 squamous arosed with invasive ductal carcinoma,7 spindled,1 mixed histologic subtypes.The median age at diagnosis of MBC was 51 years,median tumor size was 3.8 cm,and axillary lymph node involvement was 43.8%.All cases were negative for ER and PR,13 out of the 16 cases were triple-negative for ER,PR,and HER-2.Reduction or loss of membranous E-cadherin in 16 MBC,and positive expression of Vimentin was found in 62.5% MBC.The normal expression rate of E-cadherin in MBC was significantly lower than that in IDC (0% vs 37.5%,P<0.05).While expression level of Vimentin in MBC was significantly higher than that in IDC (P<0.05).Conclusion:MBC is a rare type of breast cancer with divergent cellular differentiation and histologic heterogeneity.Most of them are triple-negative with low expression of hormone receptor,and HER-2.And EMT in metaplastic breast cancer was significantly higher than IDC.Thus MBC has worse prognosis than IDC,and is resistant to comprehensive treatment.
Keywords:breast carcinoma   metaplastic carcinoma of the breast   immunohistochemistry   EMT
点击此处可从《现代肿瘤医学》浏览原始摘要信息
点击此处可从《现代肿瘤医学》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号